DE69922024D1 - Pyrrolochinoline zur Behandlung von Fettleibigkeit - Google Patents

Pyrrolochinoline zur Behandlung von Fettleibigkeit

Info

Publication number
DE69922024D1
DE69922024D1 DE69922024T DE69922024T DE69922024D1 DE 69922024 D1 DE69922024 D1 DE 69922024D1 DE 69922024 T DE69922024 T DE 69922024T DE 69922024 T DE69922024 T DE 69922024T DE 69922024 D1 DE69922024 D1 DE 69922024D1
Authority
DE
Germany
Prior art keywords
alkyl
hydrogen
disorders
cyano
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69922024T
Other languages
English (en)
Other versions
DE69922024T2 (de
Inventor
David Reginald Adams
Jonathan Mark Bentley
Jonathan Richard Anthon Roffey
Corinna Dagmar Bodkin
Howard Langham Mansell
Ashley Roger George
Ian Anthony Cliffe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligand UK Research Ltd
Original Assignee
Cerebrus Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerebrus Pharmaceuticals Ltd filed Critical Cerebrus Pharmaceuticals Ltd
Publication of DE69922024D1 publication Critical patent/DE69922024D1/de
Application granted granted Critical
Publication of DE69922024T2 publication Critical patent/DE69922024T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DE69922024T 1998-09-01 1999-09-01 Pyrrolochinoline zur Behandlung von Fettleibigkeit Expired - Fee Related DE69922024T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9819019.2A GB9819019D0 (en) 1998-09-01 1998-09-01 Chemical compounds II
GB9819019 1998-09-01
PCT/GB1999/002887 WO2000012502A1 (en) 1998-09-01 1999-09-01 Pyrroloquinolines for treatment of obesity

Publications (2)

Publication Number Publication Date
DE69922024D1 true DE69922024D1 (de) 2004-12-23
DE69922024T2 DE69922024T2 (de) 2005-09-15

Family

ID=10838154

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69922024T Expired - Fee Related DE69922024T2 (de) 1998-09-01 1999-09-01 Pyrrolochinoline zur Behandlung von Fettleibigkeit

Country Status (12)

Country Link
US (1) US6365598B1 (de)
EP (1) EP1109809B1 (de)
JP (1) JP2002523506A (de)
AT (1) ATE282613T1 (de)
AU (1) AU5637799A (de)
CA (1) CA2341986A1 (de)
DE (1) DE69922024T2 (de)
DK (1) DK1109809T3 (de)
ES (1) ES2232168T3 (de)
GB (1) GB9819019D0 (de)
PT (1) PT1109809E (de)
WO (1) WO2000012502A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9902047D0 (en) * 1999-01-29 1999-03-17 Cerebrus Ltd Chemical compounds XI
US6465467B1 (en) 1999-05-21 2002-10-15 Biovitrum Ab Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
GB9918965D0 (en) 1999-08-11 1999-10-13 Cerebrus Ltd Chemical compounds xxi
CN1227237C (zh) 2000-11-20 2005-11-16 比奥维特罗姆股份公司 作为五羟色胺5－ht2受体拮抗剂的哌嗪基吡嗪化合物
SE0004245D0 (sv) 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
US7214690B2 (en) 2001-02-23 2007-05-08 Ligand Pharmaceuticals Incorporated Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods
US7026484B2 (en) 2001-02-23 2006-04-11 Ligand Pharmaceuticals Incorporated Tricyclic androgen receptor modulator compounds and methods
AU2003243089B2 (en) 2002-06-19 2010-01-07 Biovitrum Ab (Publ) Novel compounds, their use and preparation
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
CA2495192A1 (en) * 2002-08-30 2004-03-11 Alcon, Inc. Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
GB0314967D0 (en) 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
EP1792629A4 (de) 2004-08-25 2010-08-25 Takeda Pharmaceutical Mittel zur prävention/behandlung von stressbedingter harninkontinenz und vorsorgeuntersuchungsverfahren dafür
CA2602348C (en) 2005-03-31 2011-03-01 Pfizer Products Inc. Cyclopentapyridine and tetrahydroquinoline derivatives
BRPI0609191B8 (pt) 2005-06-17 2021-05-25 Ligand Pharm Inc métodos e compostos moduladores de receptor de androgênio
WO2007053353A2 (en) * 2005-10-28 2007-05-10 Wyeth Pyrrolo[2,3-f] and [3,2-f]isoquinolinone derivatives as 5-hydroxytryptamine-6 ligands
EP1991531A1 (de) * 2006-02-28 2008-11-19 Amgen Inc. Cinnolin- und chinoxalinderivate als phosphodiesterase-10-hemmer
EP2018863B9 (de) 2006-05-16 2015-02-18 Takeda Pharmaceutical Company Limited Kondensierte, heterocyclische Verbindung und ihre Verwendung
CA2657640A1 (en) * 2006-07-14 2008-01-24 Pfizer Products Inc. Tartrate salt of (7s)-7-[(5-fluoro-2-methyl-benzyl)oxy]-2-[(2r)-2-methylpiperazin-1-yl]-6,7-dihydro-5h-cyclopenta[b]pyridine
US20100266504A1 (en) 2007-11-15 2010-10-21 Takahiro Matsumoto Condensed pyridine derivative and use thereof
KR101062376B1 (ko) 2008-04-10 2011-09-06 한국화학연구원 신규 인돌 카르복실산 비스피리딜 카르복사마이드 유도체,이의 제조방법 및 이를 유효성분으로 함유하는 조성물
JPWO2011071136A1 (ja) 2009-12-11 2013-04-22 アステラス製薬株式会社 線維筋痛症治療剤
EP3027613B1 (de) * 2013-07-25 2018-03-28 Uniwersytet Jagiellonski Pyrrolochinolin-derivate als 5-ht6-antagonisten, herstellungsverfahren und verwendung
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
JPWO2019131902A1 (ja) 2017-12-27 2020-12-10 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW270114B (de) 1993-10-22 1996-02-11 Hoffmann La Roche
TW334423B (en) 1993-10-22 1998-06-21 Hoffmann La Roche Tricyclic 1-aminoethylpyrrole-derivatives
TW403738B (en) * 1994-08-12 2000-09-01 Hoffmann La Roche Tricyclic pyrazole derivatives
WO1998030548A1 (fr) * 1997-01-13 1998-07-16 Yamanouchi Pharmaceutical Co., Ltd. AGONISTES DU RECEPTEUR 5-HT2c ET DERIVES D'AMINOALKYLINDAZOLE
AU727654B2 (en) * 1997-06-13 2000-12-21 Yamanouchi Pharmaceutical Co., Ltd. Tricyclic pyrazole derivative

Also Published As

Publication number Publication date
JP2002523506A (ja) 2002-07-30
CA2341986A1 (en) 2000-03-09
AU5637799A (en) 2000-03-21
DK1109809T3 (da) 2005-03-14
ATE282613T1 (de) 2004-12-15
PT1109809E (pt) 2005-02-28
EP1109809A1 (de) 2001-06-27
EP1109809B1 (de) 2004-11-17
WO2000012502A1 (en) 2000-03-09
DE69922024T2 (de) 2005-09-15
ES2232168T3 (es) 2005-05-16
GB9819019D0 (en) 1998-10-28
US6365598B1 (en) 2002-04-02

Similar Documents

Publication Publication Date Title
DE69922024D1 (de) Pyrrolochinoline zur Behandlung von Fettleibigkeit
HK1034967A1 (en) Pyroloindoles, pyridoindoles and azepinoindoles as5-ht2c agonists.
GB9819032D0 (en) Chemical compounds IV
HUP0202477A2 (hu) Ftalazinszármazékok alkalmazása
DE60219793D1 (de) Methode zur behandlung von zytokinvermittelten erkrankungen
AR029815A1 (es) Derivados aza-indolicos, un proceso para su preparacion, composicion farmaceutica, un metodo para su elaboracion y el uso de dichos derivados para la manufactura de un medicamento
GEP20053660B (en) Novel Tyrosine Kinase Inhibitors
YU21702A (sh) Supstituisani indoli za moduliranje nfkb aktivnosti
WO2000017170A3 (en) N1-substituted benzopyrazoles as inhibitors of 5-ht2 receptors
DE60024360D1 (de) Verwendungen und Zusammensetzungen zur Behandlung von primären und sekundären Tumoren des Zentralnervensystems (ZNS)
WO2002040461A3 (en) Aminoalkoxybiphenyl carboxamides as histamine-3 receptor ligands and their therapeutic applications
WO2000012482A3 (en) Indazole derivatives with 5-ht2 receptor activity
MXPA04007391A (es) Heterociclos triciclicos fusionados utiles para el tratamiento de padecimientos hiper-proliferantes.
MXPA06000701A (es) Compuestos de sulfonildihidrobencimidazolona como ligandos de 5-hidroxitriptamina-6.
ATE470444T1 (de) Alpha,beta-ungesättigte sulfone zur behandlung von zellenwucherungsstörungen
NO20020031L (no) Dihydrobenzodiazepiner og deres anvendelse til behandling av dyslipidemi
GB0412314D0 (en) Compounds
ATE402694T1 (de) Verwendung von 1-phenyl-3-dimethylamino-propan- verbindungen zur therapie der harninkontinenz
DK1220848T3 (da) N-arylmethylthioanilid-forbindelser, som er nyttige til inhibition af replikationen af HIV
ATE419238T1 (de) Arylsulfanyl und heteroarylsulfanyl-derivate zur behandlung von schmerz
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: VERNALIS RESEARCH LTD., WINNERSH, WOKINGHAM, GB

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee